The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Open accessAbstract
BACKGROUND: In patients with human immunodeficiency virus (HIV) infection, combined treatment with several agents may increase the effectiveness of antiviral therapy. We studied the safety and efficacy of saquinavir, an HIV-protease inhibitor, given with one or two nucleoside antiretroviral agents, as compared with the safety and efficacy of a combination of two nucleosides alone. METHODS: In this double-blind trial, patients with HIV infection were randomly assigned to receive either saquinavir (1800 mg per day) plus both zidovudine (600 mg per day) and zalcitabine (2.25 mg per day) or zidovudine plus either saquinavir or zalcitabine. The 302 patients enrolled had CD4+ counts of 50 to 300 cells per cubic millimeter and had previously received zidovudine for a median of 27 months. The study lasted 24 weeks, with an optional double-blind extension period of an additional 12 to 32 weeks. RESULTS: Ninety-six percent of the patients completed the 24-week study. In all three treatment groups, CD4+ cell counts rose at first and then fell gradually. The normalized area under the curve for the CD4+ count was greater with the three-drug combination than with either saquinavir and zidovudine (P=0.017) or zalcitabine and zidovudine (P<0.001). There were significantly greater reductions in plasma HIV with the three-drug combination than with the other regimens when peripheral-blood mononuclear cells were cultured for HIV and HIV RNA was assessed, and there were greater decreases in serum neopterin and beta2-microglobulin levels. There were no major differences in toxic effects among the three treatments. CONCLUSIONS: Treatment with saquinavir, zalcitabine, and zidovudine was well tolerated. This drug combination reduced HIV-1 replication, increased CD4+ cell counts, and decreased levels of activation markers in serum more than did treatment with zidovudine and either saquinavir or zalcitabine. Studies are warranted to evaluate whether the three-drug combination will reduce morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Larder, B. A., Darby, G., & Richman, D. D. (1989) · Science · doi:10.1126/science.2467383 · Cited by 1,559
The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
Larder, B. A., & Kemp, S. D. (1989) · Science · doi:10.1126/science.2479983 · Cited by 1,163
Surveillance for dracunculiasis, 1981-1991.
Hopkins, D. R., & Ruiz‐Tiben, E. (1992) · PubMed · Cited by 1,110
Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS
O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., & Hamilton, J. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602153340703 · Cited by 720
Mulder, J., McKinney, N., Christopherson, C., Sninsky, J., Greenfield, L., & Kwok, S. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.2.292-300.1994 · Cited by 558
A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation
McQuade, T. J., Tomasselli, A. G., Liu, L., Karacostas, V., Moss, B., Sawyer, T. K., Heinrikson, R. L., & Tarpley, W. G. (1990) · Science · doi:10.1126/science.2405486 · Cited by 374
Kahn, J. O., Lagakos, S. W., Richman, D. D., Cross, A., Pettinelli, C., Liou, S.-H., Brown, M., Volberding, P. A., Crumpacker, C. S., Beall, G., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208273270901 · Cited by 347
Self-citationExact Significance Testing to Establish Treatment Equivalence with Ordered Categorical Data
Mehta, C. R., Patel, N. R., & Tsiatis, A. A. (1984) · Biometrics · doi:10.2307/2530927 · Cited by 328
HTLV-III gag Protein Is Processed in Yeast Cells by the Virus pol -Protease
Kramer, R. A., Schaber, M. D., Skalka, A. M., Ganguly, K., Wong-Staal, F., & Reddy, E. P. (1986) · Science · doi:10.1126/science.2420008 · Cited by 287
Zidovudine and the Natural History of the Acquired Immunodeficiency Syndrome
Moore, R. D., Hidalgo, J., Sugland, B. W., & Chaisson, R. E. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242006 · Cited by 278
Pachl, C. A., Todd, J. A., Kern, D. G., Sheridan, P. J., Fong, S.-J., Stempien, M. M., Hoo, B., Besemer, D. J., Yeghiazarian, T., Irvine, B. D., et al. (1995) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199504120-00003 · Cited by 232
Abrams, D. I., Goldman, A. I., Launer, C., Korvick, J. A., Neaton, J. D., Crane, L. R., Grodesky, M., Wakefield, S., Muth, K., Kornegay, S., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301001 · Cited by 214
Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex
Fischl, M. A. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430170067030 · Cited by 200
Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
Craig, J. C., Duncan, I. B., Hockley, D., Grief, C., Roberts, N. A., & Mills, J. S. (1991) · Antiviral Research · doi:10.1016/0166-3542(91)90045-s · Cited by 189
Ashorn, P., McQuade, T. J., Thaisrivongs, S., Tomasselli, A. G., Tarpley, W. G., & Moss, B. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7472 · Cited by 186
Survival Experience Among Patients With AIDS Receiving Zidovudine
Creagh-Kirk, T. (1988) · JAMA · doi:10.1001/jama.1988.03410200065027 · Cited by 171
Dewar, R. L., Highbarger, H. C., Sarmiento, M. D., Todd, J. A., Vasudevachari, M. B., Davey, R. T., Kovacs, J. A., Salzman, N. P., Lane, H. C., & Urdea, M. S. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/170.5.1172 · Cited by 166
Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease
Fischl, M. A., Stanley, K., Collier, A. C., Arduino, J. M., Stein, D. S., Feinberg, J., Allan, J. D., Goldsmith, J. C., & Powderly, W. G. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00004 · Cited by 123
Self-citationJohnson, V. A., Merrill, D. P., Chou, T., & Hirsch, M. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/166.5.1143 · Cited by 75
Vella, S. (1992) · JAMA · doi:10.1001/jama.1992.03480090080031 · Cited by 75
Lambert, D. M., Petteway, S. R., McDanal, C. E., Hart, T. K., Leary, J. J., Dreyer, G. B., Meek, T. D., Bugelski, P. J., Bolognesi, D. P., & Metcalf, B. W. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.5.982 · Cited by 65
Antiviral Synergy between Inhibitors of HIV Proteinase and Reverse Transcriptase
Craig, J. C., Duncan, I. B. R., Whittaker, L., & Roberts, N. A. (1993) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029300400305 · Cited by 34
Craig, J. C., Whittaker, L., Duncan, I. B. R., & Roberts, N. A. (1994) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029400500605 · Cited by 27
Cited by
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,885
Autran, B., Carcelain, G., Li, T. S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debré, P., & Leibowitch, J. (1997) · Science · doi:10.1126/science.277.5322.112 · Cited by 1,785
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351501 · Cited by 1,091
Self-citationKim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Metadata
- Authors
- Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., & Corey, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-04-18
- Volume
- 334
- Issue
- 16
- Pages
- 1011-1018
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2339827976
- Cited by
- 745
- References
- 25
- FWCI
- 92.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.